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Background:  Latent  tuberculosis  has  been  associated  with  the  persistence  of dormant  Mycobac-
terium  tuberculosis  in  the  organism  of  infected  individuals,  who  are reservoirs  of  the  bacilli
and the  source  for  spreading  the  disease  in the  community.  New  active  anti-TB  drugs  exerting
their metabolic  action  at different  stages  and  on  latent/dormant  bacilli  are  urgently  required
to avoid  endogenous  reactivations  and  to  be  part  of  treatments  of  multi-  and  extensively-drug
resistant tuberculosis  (M/XDR-TB).  It  was  previously  reported  that  azole  drugs  are active  against
M. tuberculosis.  For  that  reason,  the aims  of  this  study  were  to  determine  the  in  vitro  activity
of azole  drugs,  imidazole  (clotrimazole,  CLO  and  econazole,  ECO)  and nitroimidazole  (metron-
idazole, MZ  and  ipronidazole,  IPZ),  against  a  collection  of  MDR  M.  tuberculosis  clinical  isolates;
and to  analyze  their  potential  use  in  both  the  LTB and the  active  forms  of  M/XDR-TB  treatments.
Methods: A  total  of  55  MDR  M.  tuberculosis  isolates  and  H37Rv  were  included.  MZ  and
IPZ activity  against  M.  tuberculosis  isolates  were  tested  using  anaerobic  culture  conditions.
The activity  of  ECO  and  CLO  was  measured  by  the  minimal  inhibitory  concentration  (MIC)  using
a microdilution  colorimetric  method.
Results: MZ  and  IPZ  showed  bacteriostatic  activity  against  M.  tuberculosis  strains.  MIC50 and
MIC90 to  ECO  was  4.0  g/ml,  while  MIC50 to  CLO  was  4.0  g/ml  and  MIC90 was  8.0  g/ml  respec-
tively.
Conclusion:  All  azole  compounds  tested  in  the  study  showed  inhibitory  activity  against  MDR
M. tuberculosis  clinical  isolates.
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Actividad  in vitro  de  azoles  contra  aislamientos  clínicos  de  Mycobacterium
tuberculosis
Resumen
Introducción:  La  tuberculosis  (TB)  latente  ha  sido  asociada  a  la  persistencia  de  Mycobacterium
tuberculosis  durmientes  en  el organismo  de  las  personas  infectadas,  las  cuales  constituyen  un
reservorio del  bacilo  y  una  fuente  de diseminación  de la  enfermedad  en  la  comunidad.  Urge
la necesidad  de  contar  con  nuevos  fármacos  antituberculosos  con  acción  sobre  el bacilo  en
estado latente/durmiente,  a  fin  de  evitar  reactivaciones  endógenas  y  para  ser  incluidas  en  el
tratamiento  de  la  TB multirresistente  y  extensivamente  resistente  (M/XDR-TB).  Se  ha  reportado
que los  azoles  son  activos  contra  M.  tuberculosis.  Por  esta razón,  los  objetivos  del  presente
estudio fueron  determinar  la  actividad  in vitro  sobre  aislamientos  clínicos  de M/XDR-TB  de
distintos azoles,  incluyendo  los  imidazoles  econazol  (ECO)  y  clotrimazol  (CLO)  y  los  5-nitro-
imidazoles  ipronidazol  (IPZ)  y  metronidazol  (MZ),  así  como  analizar  su  potencial  uso  contra  las
formas latente  y  activa  de  esta  enfermedad.
Métodos:  Fueron  incluidos  55  aislamientos  clínicos  de  M. tuberculosis  MDR  y  la  cepa  de  refer-
encia H37Rv.  Se  evaluó  la  actividad  del  MZ  y  el IPZ  sobre  los  aislamientos  en  condiciones  de
cultivo anaeróbico,  mientras  que  la  actividad  del  ECO  y  el  CLO  fue  estimada  determinando  la
concentración  inhibitoria  mínima  (CIM)  mediante  el  método  colorimétrico  de microdilución  en
placa.
Resultados:  El  MZ  y  el  IPZ  presentaron  actividad  bacteriostática  frente  a  las  cepas  de M.  tuber-
culosis. La  CIM50 y  CIM90 del  ECO  fue de 4 g/ml,  mientras  que  el CLO  presentó  una  CIM50 de
4 g/ml  y  una CIM90 de  8 g/ml.
Conclusión:  Todos  los  compuestos  azólicos  evaluados  presentaron  actividad  inhibitoria  frente  a
aislamientos  clínicos  de  M. tuberculosis.
©  2017  Asociación  Argentina  de Microbioloǵıa.  Publicado  por  Elsevier  España,  S.L.U.  Este  es  un
art́ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Latent  tuberculosis  (LTB)  has been associated  with  the
persistence  of dormant  Mycobacterium  tuberculosis  in the
organism  of  infected  individuals,  who  are reservoirs  of
the  bacilli  and  the  source for spreading  the disease  in the
community10.
The Word  Health  Organization  (WHO)  estimates  that
one-third  of  the world  population  is  infected  with  M.  tuber-
culosis  and  around  10%  might develop  the disease  during
their  life31,32.  In  2013,  it was  estimated  that  almost  480
000  new  multidrug-resistant  tuberculosis  (MDR-TB,  simul-
taneously  resistant  to  isoniazid,  INH,  and  rifampicin,  RIF)
cases  occurred  worldwide.  The  extensively  drug-resistant
TB  (XDR-TB)  caused  by MDR  microorganisms  with  resistance
also  to an  injectable  agent  (amikacin,  kanamycin  or  capre-
omycin)  and  to a  fluoroquinolone,  has  been  reported  by  100
countries  and  in  accordance  with  the  WHO,  around  9.0% of
people  with  MDR-TB  have  XDR-TB9.
From  year  2000  to  2012,  Argentina  reported  more  than  80
XDR-TB  cases  with  2.2%  of  incidence  rate  among  new  MDR-TB
cases15.
XDR-TB  is considered  an  almost  incurable  disease  and
a  limited  number  of  active antibiotics  that  could  be  used
are  available.  The  contacts  of  M/XDR  cases  could  also  be
infected  by  these  resistant  mycobacteria,  developing  and
spreading  the  disease  in  the community.  Therefore,  new
active  anti-TB  drugs  exerting  their  metabolic  action  at
different  stages  and on  latent/dormant  bacilli  are  urgently
required  to  avoid  endogenous  reactivations  and to  be part
of  treatments  for  M/XDR-TB.
Azole  drugs, such  as  imidazole,  econazole  (ECO)  and
clotrimazole  (CLO)  are widely  used  antifungal  agents,  which
are  also  active against  some gram  positive  bacteria.  There
are  many  data  on  their  safety,  side  effects,  pharmacoki-
netics  and  pharmacodynamics4,32.  Furthermore,  it  has  been
previously  reported  that  azoles  are also  active  against
in  vitro  M.  tuberculosis  and  in the mouse  model2,17,18,24.
The  distribution  of  Cytochrome  P450 (CYP)  mono-
oxygenases  in  fast-growing  and  slow-growing  mycobacteria
evidence  that these  enzymes  are highly  conserved  in the
genus  Mycobacterium  unlike  other  bacteria  having  no  CYP,
such  as  Escherichia  coli. Azole  drugs  coordinate  to  the heme
iron of  CYPs of  the microorganism;  therefore,  they  are
potent  CYP inhibitors.  M.  tuberculosis  contains  20  differ-
ent  CYPs11,12,19,23. There  is  no  doubt  about  the  activity  of
some  azoles  against  mycobacteria  such us PA824,  metron-
idazole  (MZ),  delamanid,  ECO,  CLO and  many  new  molecules
of  chemical  synthesis;  however,  their  mechanism  of action
is  not fully  elucidated20,24. It  has  been  postulated  that  the
main  mechanism  of resistance  to  azoles  is  the  increased
drug  efflux  mediated  by  the  MmpS5-MmpL5  system  in
M.  tuberculosis11,16,24.
Antimicrobial  drugs  that  showed  no  significant  activity
against  M. tuberculosis  in aerobic  culture  condition  may  be
active  in the  dormant  state  induced  by  a drop  of  the oxygen
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tension  in  the  culture  medium.  This  suggests  the  possibil-
ity  that  these  drugs  may  have  a  place  in  the chemotherapy
of  MDR-TB  and  LTB  alone  and/or  in  combination  with  other
drugs28.
Nitroimidazoles  are synthetic  chemotherapeutic  agents
that  are  active  against  fungi,  parasites  and anaerobic  bac-
teria,  and  which  have  also  demonstrated  their  bactericidal
activity  against  dormant  M.  tuberculosis, since  the targets
of  these  drugs  are  expressed  during  the latent  state1,3.  It has
been  postulated  that these  drugs exert  bactericidal  activity
by  the  reduction  of  its  nitro  group.  Although  5-nitro  and 2-
nitroimidazoles  are available,  only the  5-nitro  derivative  is
effective  as  antibacterial  and  antiparasitic  agent14.  MZ  is  the
main  drug  of  5-nitroimidazoles  and  it is  believed  that  it acts
as  an  electron  acceptor,  inhibiting  the  released  H2 and  ATP
production.  The  active  structure  of MZ  remains  unknown;
however  MZ  reduction  requires  three  electrons;  therefore
it  is  supposed  that  there  is  a free  radical  or  another  highly
electrophilic  molecule  acting  as  electron  acceptor.  Reduced
MZ  derivatives  act  on  DNA,  producing  an extensive  break  of
this  molecule  as  well  as, it is  believed,  a possible  inhibition
of  DNA  repair  mechanisms5.  It  has also  been  postulated  that
MZ  is active  against M. tuberculosis  by  affecting  the  synthe-
sis  of  fatty  acids  in mycobacteria22.  The  redox potential  of
MZ  is −420  mV  and  the  lowest  potential  in aerobic  systems  is
−350  mV,  for  this reason,  MZ  is  only  active  under  anaerobic
conditions.
MZ  acts  on  gram  positive,  gram  negative  and anaer-
obic  bacteria.  The  antiparasitic  effect  includes  amebas,
trichomonas  and  giardias.  In  M. tuberculosis, MZ  is  consid-
ered  a  prodrug  that is activated  by  mycobacterium  enzymes,
such  as  the  oxidoreductase  formed  by  Rv2454c  and  Rv2455c.
This  enzyme  would  be  expressed  around  day  25th of  incuba-
tion  under  hypoxic  culture conditions12,13. Genes  codifying
for  CYP450  are  essential  for  the virulence  and  persistence  of
M.  tuberculosis  in the host.  It has  been  previously  reported
that  under  hypoxic  conditions,  MZ  has bactericidal  activity
against  non-replicating  M. tuberculosis25.
Some  clinical  trials  evaluated  MZ  activity  for  pulmonary
TB  demonstrating  that  it produced  early  sputum  smear  and
culture  negative  conversions  but  it was  too  neurotoxic  and
hepatotoxic  to  be  part  of  a long  term  anti-TB  treatment8.
Moreover,  delamanid  is  a MZ  derivative  recently
approved  for  MDR-TB  treatment  in combination  with
other  anti-TB  drugs (http://ec.europa.eu/health/
documents/community-register/2015/20150424131446/
anx  131446  es.pdf).
The  aims  of this  study  were  to  determine  the in  vitro
activity  of  azole  drugs,  imidazole  and nitroimidazole  against
a  collection  of  MDR  M.  tuberculosis  clinical  isolates  to  com-
pare  the  activity  of  MZ  with  IPZ  and  among  imidazoles  ECO
and  CLO,  and  to analyze  their  potential  use  in both  LTB  and
the  active  forms  of M/XDR-TB  treatments.
In this  study  we  tested  MZ  and IPZ  as  a prototype  of  5-
nitroimidazole  compounds.
IPZ (2-isopropyl-1-methyl-5-nitroimidazole)  is  an
antiprotozoal  drug  similar  to MZ  that  had  been  used in vet-
erinary  medicine,  such  as  in  the treatment  of  histomoniasis,
swine  dysentery,  trichomoniasis  and  giardiasis  in turkeys
and  dogs26,30.  In our  knowledge  there  are  no  previous
reports  testing  the in  vitro  activity  of  IPZ  on  M. tuberculosis
strains.
Table  1  Number  and  percentages  of  M.  tuberculosis  strains
considered  to  be susceptible  for  each  one  of  the  drugs  from
the REMA  and  hypoxia  experiments
Drug  concentration  (g/ml)  Susceptible  strains
n (%)
Metronidazolea
8.0  36  (65.5)
32.0 52  (94.5)
Ipronidazole
16.0 25  (100.0)
Econazole
4.0  55  (100)
Clotrimazole
16.0 55  (100.0)
a Three strains showed invalid results.
On the  other  hand,  ECO and  CLO  were  used  to test  the
imidazole  activity  among  our  MDR M. tuberculosis  clinical
isolates.
Metronidazole                    Ipronidazole
 
Materials and methods
A retrospective  study  including  a collection  of MDR
M.  tuberculosis  strains  isolated  from  patients  diagnosed  in
the  Reference  Laboratory  of Tuberculosis  Control  Program
at  Dr.  Cetrangolo  Hospital  was  conducted.
The  Informed  consent  from  each patient  was  obtained
at  the  moment  of the  bacteriological  TB diagnostic  was
made.  No  ethical  approval  was  required  for  this  study  since
it was  a retrospective  study  that  only  included  M. tubercu-
losis  isolates and these  experiences  did  not interfere  with
treatment  decisions  or  medical  behavior.  However,  approval
was  obtained  from  the Ethical  Committee  of  Dr.  Cetrangolo
Hospital  at  the  moment  of  the  study  design.
M.  tuberculosis  strains and clinical  isolates
A total  of  55  MDR M.  tuberculosis  strains  were  included  in the
study.  This  collection  of MDR-TB  strains  were  kept  at −20 ◦C
and  at the moment  of  the  study  they  were unfrozen  and  sub-
cultured  in fresh Middlebrook  7H9  broth  (M7H9)  with  OADC
enrichment  (Becton  Dickinson,  Buenos  Aires,  Argentina).
M.  tuberculosis  H37Rv  ATCC  27294 was  used  as  fully  drug-
susceptible  reference  strain  (Table  1).
MZ and  IPZ  activity
In  vitro  latency  model
To obtain  anaerobic  M. tuberculosis  cultures  (Can),  a sys-
tem  adapted  from  Wayne  and  Hayes29.  was  used.  Briefly,
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vacuum  5  ml Vacutainer  tubes  (Becton  Dickinson,  Buenos
Aires,  Argentina)  were  filled,  using  syringe  and needle  (26
½),  with  3.0  ml M7H9/OADC.  Then, the tubes  were  inoc-
ulated  with  30  l  1:100  dilution  from  a M. tuberculosis  1
McFarland  suspension  that  was  in the  middle  of  the  expo-
nential  phase  of the growth  curve  and  previously  passed
three  times  by  syringe  and  needle  (26  ½).  These  tubes  were
immediately  incubated  at 37 ◦C during  35  days  to achieve
the  hypoxic  condition.  Hypoxia  is  indicated  by  discoloration
in  the  ‘control  discoloration  tube’,  which  was  prepared  as
above  mentioned  but  also adding  1.5  mg/l  of  methylene
blue  (MB).  MB is  decolorized  when  the culture  achieves  the
hypoxic  condition27,29.
In  vitro  activity  of  MZ  and  IPZ in anaerobiosis
MZ  (Fluka,  VETRANALTM,  USA):  once  cultures  of  M.  tuber-
culosis  (H37Rv  and  MDR clinical  isolates)  reached  hypoxia,
8.0  g/ml  and  32.0  g/ml  of MZ  (Fluka,  Germany)  were
added  in  different  tubes  to  determine  MZ  activity.  A free-
drug  tube  was  used  as  control  of  mycobacterial  growth.
IPZ (Sigma--Aldrich,  USA):  once  M.  tuberculosis  H37Rv
achieved  the  hypoxic  condition,  8.0 g/ml,  16.0  g/ml,
32.0  g/ml,  64.0  g/ml and 128.0  g/ml  were added  to
determine  their  activity.  MDR  M. tuberculosis  isolates  were
tested  at  16.0  g/ml  and 128.0  g/ml.  A free-drug  tube was
used  as  control  of  mycobacterial  growth.
In  both  cases  (MZ/IPZ),  the  tubes  were  immediately  re-
incubated  for 15  days  at 37 ◦C.
Determination  of time to  exit  from  the
hypoxic/dormant  state
After  15  incubation  days,  and  in order  to  remove  the  MZ/IPZ
from  the  drug-containing  tubes,  the whole  content  was
transferred  to  a 15.0  ml sterile  empty  plastic  tube  and  was
centrifuged  at 3000  rpm  for  10  min  in a refrigerated  cen-
trifuge.  The  supernatant  was  removed  and the  pellet  was
washed  with  3.0  ml of PBS 1X, vortexing  gently  and  cen-
trifuging  again.  Afterwards,  the pellet  was  resuspended  in
3.0  ml  of  PBS  1X.  Then, 500.0 l  of  the washed  culture  were
loaded  into  a BACTEC  MGIT  960/OADC  tube  (Becton  Dick-
inson,  Buenos  Aires,  Argentina)  to evidence  the inhibitory
effect  of  the drugs.  The  EpiCenter  Software  (Becton  Dickin-
son,  Buenos  Aires,  Argentina)  connected  to the  MGIT  system
was  used  to  detect  the  growth  units,  indicating  the  exit  of
dormancy  and  the  restoration  of the cellular  metabolism  in
aerobic  conditions6.
ECO  and  CLO  activity
Determination  of  the  minimal  inhibitory  concentration  (MIC)
to  ECO  and  CLO  was  performed  by  the  previously  described
resazurin  (RES)  microtiter  assay  using  96-well  microplates.
RES  is a  redox  indicator  that  changes  the color  when  bac-
teria  consume  O2. Briefly,  the outside  wells were  filled
with  200  l of  sterile  water  and  the inside  wells  with
100  l  of  M7H9/OADC  medium.  Afterwards,  100 l of  ECO
or  CLO  were  added,  the initial drug concentration  being
32.0  g/ml;  then  two-fold  serial  dilutions  were  performed
up  to  a  lower  concentration  of  1.0  g/ml  of  the drug (range:
16.0--8.0--4.0--2.0--1.0--0.5  g/ml).  After adding  the  drugs






















Figure  1 Activity  of  metronidazole  against  M. tuberculosis
strains.  UC  CTR,  growth  units  of strains  without  metronidazole;
UC MZ8,  growth  units  of  strains  with  8.0  g/ml  of  metron-
idazole;  UC  MZ32,  growth  units  of strains  with  32.0  g/ml  of
metronidazole.
(except  in the  growth  control  well,  GC),  100  l of  a 1/25
dilution  from  1 McFarland  standard  mycobacterial  suspen-
sion,  containing  106--108 CFU/ml  were  added  in each one  of
the  wells  loaded  into  the plates.
The  plates  were  light-protected  and incubated  for  5 days
at  37 ◦C.  Then,  the GC  was  filled  with  30  l  of RES  and incu-
bated  for  one  more  day.  If no  color change  was  evidenced,
a  second  GC well  was  developed  and  incubated  for  24 h  (h)
more  and so  on.  When  bacterial  growth  was  observed,  the
remaining  wells  were  filled  with  RES  and re-incubated  for
24  h  more  for  the final  reading.  The  MIC  was  defined  as
the  lowest  drug  concentration  that  completely  inhibited  the
microorganism  growth,  which  was  evidenced  by  the absence
of  color  change  of  the  indicator21.
Statistics
Variable  summary  statistics  were  determined  by  the Med-
Calcv.  16.4.3  software  (Mariakerke,  Belgium).  The  t-test  and
the  multiple  line  graphs  to  determine  the  MZ,  IPZ,  ECO and
CLO activity  was  used to  estimate  the significance  of  the
differences  between  drug activity  against  M.  tuberculosis.
Results
Metronidazol  and  Ipronidazol
MZ  was  tested  as  onH37Rv  and on  a  total  of  55 MDR
M.  tuberculosis  strains.  A total  of  52  (94.5%)  M.  tubercu-
losis  strains  showed  valid  and  interpretable  results.  Figure 1
shows  the  global  activity  of MZ  against  M.  tuberculosis
strains,  with  a  difference  of  approximately  2  logarithmic
units  (2 Ulog,  p  < 0.0001)  between  the  drug-free  tube  and MZ
(8.0  and  32.0  g/ml)-containing  tubes  when  the mycobacte-
ria  reached  the  exponential  growth  phase.  This  difference
diminishes  throughout  the growth  curve,  and at the mid  of
the  log  phase  a difference  of  1.0  Ulog  between  the control
tube  and  the MZ  (8.0  g/ml)-containing  tube  was  observed
(p  <  0.0001)  while  the difference  between  control  tube  and
MZ  (32.0  g/ml)  was  0.4  Ulogs  (p  < 0.0001);  furthermore,  no
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Figure  2  Metronidazole  activity  against  dormant  M.  tuber-
culosis  strains  in  different  phases  of  the  growth  curve.
(a) UC  To  CTR/UC  To  Mz8/UC  To  Mz32,  growth  units  to  reach
the logarithmic  phase  of the  strains  without  metron-
idazole/8.0  g/ml  of  metronidazole/32.0  g/ml  of  metron-
idazole.  (b)  UC  T1  2 CTR/UC  T1  2  Mz8/C  T1 2 Mz32,  growth
units at  the  mid  of  the  logarithmic  phase  of  the  strains
without  metronidazole/8.0  g/ml/32.0  g/ml  of  metronida-
zole. (c)  UC  Te  CTR/UC  Te  Mz8/UC  Te  Mz32,  growth  units  at
the stationary  phase  of  the  strains  without  metronida-
zole/8.0  g/ml/32.0  g/ml  of  metronidazole.
significant  difference  was  observed  between  both  MZ  tested
concentrations  (p  > 0.01).  There  was  no  difference  between
the  Ulog  control  tube  and the MZ-containing  tubes  (Ulog  0.06
and  0.12  for  MZ  8.0  and MZ  32.0  g/ml  respectively,  p >  0.01)
at  the  moment  in which the mycobacterium  growths  reached
the  stationary  phase.
Figure  2  shows  the  difference  in each  phase  of  the  curve
for  each  MZ  concentration.
To  determine  IPZ  activity,  this drug was  first  tested  on
M.  tuberculosis  H37Rv  strain.  An  increased  inhibitory  effect






































H37Rv_IPZ_16  µg/ml H37Rv_IPZ_32_µg_ml
H37Rv_IPZ_64_ µg_ml H37Rv_IPZ 128  µg_ml
Figure  3  Effect  of  different  concentrations  of  ipronidazole
(IPZ)  on  M. tuberculosis  H37Rv.
increasing.  Figure 3 shows  the effect  at different  concen-
trations  of  IPZ  on  dormant  M. tuberculosis  H37Rv.
IPZ  activity  at 16.0  g/ml  and  128.0  g/ml  was  also
tested  on  25  MDR M.  tuberculosis  isolates.  Figure  4  shows
the  difference  in each phase  of  the curve  for  each  one  of the
IPZ  concentrations  tested  on  the M. tuberculosis  isolates.
As  Figure  4  shows,  greater  activity  was  observed  using IPZ
128.0  g/ml  than 16.0  g/ml (p  <  0.001)  at the  mid  of the
log  phase, while  in the stationary  phase,  no  difference  was
observed  between  both  concentrations  tested  (p  >  0.01).
Moreover,  the  25  MDR M. tuberculosis  clinical  isolates  were
inhibited  by  both  5-nitro-imidazole  drugs.
Econazol  and  clotrimazol
ECO  and  CLO  showed  inhibitory  activity  against  H37Rv  and
MDR M. tuberculosis  clinical  isolates.  MIC  results  were  as
follows:  MIC:  0.5  g/ml (ECO,  n:  8, 14.5%;  CLO,  n: 6,
10.9%),  MIC:  2.0  g/ml  (ECO,  n: 6, 10.9%;  CLO,  n: 9, 16.4%),
MIC:  4  g/ml  (ECO,  n:  41, 74.5%;  CLO,  n:  15,  27.3%),  MIC:
8.0  g/ml (CLO,  n:  17,  30.9%),  MIC:  16.0  g/ml  (CLO,  n:  8,
14.5%).  MIC50--90 to  ECO  was  4.0  g/ml,  while  MIC50 and  MIC90
to  CLO  was  4.0  g/ml  and 8.0  g/ml  respectively.
Discussion
In this  study  and under  the system  used,  MZ  showed
a  reversible  inhibitory  bacteriostatic  activity  against
MDR M. tuberculosis  strains,  although  bacterici-
dal  activity  of  MZ  was  previously  reported  by  other
authors28.  Long-term  (35-day-old)  non-replicating
M.  tuberculosis  was  not  sterilized  after  15-day-exposure
to  MZ. The  combination  of  azole  drugs plus  other  anti-TB
agents  could  increase  the  effect  of  this kind  of  drugs12.
At  the  concentrations  of  MZ  and  IPZ  tested, a delay  was
obtained  in M. tuberculosis  growth  that  was  re-established
in  the  stationary  phase.  This  may  suggest  that  the main-
tenance  of  constant  drug  serum  levels  attained  by  the
dose  scheme  based  on the  half-life  of  the drug,  might
potentially  produce  a prolonged  inhibitory  effect,  and
could  be an  effective  alternative  in  MDR-TB  treatment  or
in the  chemoprophylaxis  of  MDR-LTB.  According  to  previous
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Figure  4  Ipronidazole  activity  against  dormant  MDR  M. tuber-
culosis  clinical  strains  in different  phases  of  the  growth
curve.  (a)  UC  To  CTR/UC  To  IPZ16/UC  To  IPZ128,  growth  units
to reach  the  logarithmic  phase  of  the  strains  without  ipronida-
zole/16.0  g/ml  of  ipronidazole/128.0  g/ml  of  ipronidazole.
(b) UC  T1  2  CTR/UC  T1  2 IPZ  16/C  T1  2  IPZ128,  growth  units
at the  mid  of  the  logarithmic  phase  of the  strains
without  ipronidazole/16.0  g/ml/128.0  g/ml  of  ipronida-
zole. (c)  UC  Te  CTR/UC  Te  IPZ16/UC  Te  IPZ128:  growth  units
at the  stationary  phase  of  the  strains  without  ipronida-
zole/16.0  g/ml/128.0  g/ml  of  ipronidazole.
reports,  an  average  of  8.0  g/ml (13.0  ±  2.3  g/ml)  is
reached  in  humans  using  doses  of  400  mg  of  MZ7,13.  In this
study  no  inhibitory  differences  were  observed  using  either
8.0  g/ml  or 32.0  g/ml  of  MZ.
Furthermore,  the fact  that  IPZ  has  also  been  tested
on  M.  tuberculosis  provides  new  preliminary  data  about
the  inhibitory  effect  of  another  compound  of  the  5-
nitroimidazole  family.  In this study  and under  our  tested
conditions,  unlike  what  was  observed  with  MZ,  IPZ inhibited
M.  tuberculosis  growth  and  the  greater  the concentra-
tion  of  the  drug  tested,  the greater  the inhibitory  effect.
These  observed  differences  could  be related  to  the  action
mechanism  of  each  drug and  with  their  pharmacokinetic
characteristics.  As  observed  with  MZ,  the inhibitory  effect  of
IPZ  was  also  bacteriostatic.  No previous  reports  exist about
the  use  of  IPZ  in  humans.  It  has been  used as  antiproto-
zoal  agent  in animals.  IPZ  is  effective  by  oral administration
in drinking  water  and  feed  and  also  by  parenteral  admin-
istration,  i.e., subcutaneous,  intramuscular,  intravenous,
intraperitoneal  or  intraruminal  injection.
Although  we  used  a Wayne  adapted  hypoxic  system  based
on  oxygen deprivation  to  test  nitroimidazole  compounds,  a
bacteriostatic  and  non-bactericidal  effect  of  these kinds  of
drugs  was  observed  on  M. tuberculosis  strains.  It could  sug-
gest  that  a  change  in the  conditions  to  achieve  the  hypoxic
culture  --  like  fatty  acid  deprivation  in  the liquid  medium  --,
could  produce  a  bactericidal  effect  of nitroimidazole  com-
pounds.
Regarding  ECO and  CLO,  the activity  against  M. tuber-
culosis  isolates  was  evidenced  under  aerobic  conditions.
Furthermore,  it  was  possible  to  find  the  MIC  value  inhibiting
most  of  the mycobacterial  amount,  suggesting  their possi-
ble  use  in combination  with  other  anti-TB  drugs  for MDR-TB
treatment.
Both  systems  used in  this  study,  allowed  us  to  evaluate
the  azole  activity  against  M.  tuberculosis  strains.  MZ,  IPZ,
ECO  and  CLO showed  activity  against  the H37Rv  strain  and
on MDR-TB  clinical  isolates.
ECO  as  well  as  CLO were  found  to  have  strong  antimy-
cobacterial  potential  against  M. tuberculosis  under  in vitro
conditions.
This  study  shows  that azole  drugs  exerted  an inhibitory
action  among  a  collection  of  Argentinean  MDR  clinical  iso-
lates.  Azole  drugs  bear  significant  therapeutic  potential
against  M.  tuberculosis.
Although  the use  of  MZ  for  TB  treatment  has  been  dis-
carded  due  to  its  adverse  effects,  both  5-nitroimidazoles
tested  in  this  study  were  used  as a model  of  their  class of
drugs.  Results  obtained  with  both  drugs  suggest  that  simi-
lar  kinds  of  drugs,  with  fewer  side  effects  than  MZ,  could
be  effective  in MDR-TB  treatment  and  in  the treatment  of
MDR-LTB  caused  by  contact  with  an  MDR-TB  source.
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